Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
Institut du Cancer de Montpellier - Val d'Aurelle
Washington University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Trials Ireland
National Cancer Institute (NCI)
AstraZeneca
Taiho Oncology, Inc.
Jazz Pharmaceuticals
Beth Israel Deaconess Medical Center
Bayer
Seagen Inc.
Actuate Therapeutics Inc.
EXACT Therapeutics AS
University of Arizona
Ruijin Hospital
HonorHealth Research Institute
Institut de Cancérologie de Lorraine
Dana-Farber Cancer Institute
Washington University School of Medicine
Bristol-Myers Squibb
Ruijin Hospital
Eastern Cooperative Oncology Group
Minia University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Allist Pharmaceuticals, Inc.
Sun Yat-sen University
Astellas Pharma Inc
Yale University
Hoffmann-La Roche
Institut Bergonié
National Cancer Institute (NCI)
Medical College of Wisconsin
BicycleTx Limited
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Psyence Australia Pty Ltd
Akeso
Massachusetts General Hospital
Hangzhou Converd Co., Ltd.
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Centre Leon Berard
Ohio State University Comprehensive Cancer Center
Zhejiang University
Zhejiang University